Review: Risk of Cerebrovascular Adverse Events and Death in Elderly Patients With Dementia When Treated With Antipsychotic Medications: A Literature Review of Evidence

Abstract

Behavioral and Psychological Symptoms of Dementia (BPSD) are increasingly recognized as a major risk factor for caregiver burden, institutionalization, greater impairment in activities of daily living (ADLs), more rapid cognitive decline, and a poorer quality of life. BPSD contribute significantly to the direct and indirect costs of caring for patients with dementia even after adjusting for the severity of cognitive impairment and other co-morbidities. Research on these symptoms has indicated a complex interplay between the biological, psychological and social factors involved in the disease process. Although some psychotropic medications have shown modest efficacy in the treatment of these behaviors, their use has generated controversy due to increasing recognition of the side effects of these medications especially the antipsychotic medications. In this review, we examine the risk of cerebrovascular adverse events (CVAEs) and death with antipsychotic medications when used to treat elderly patients with dementia.

Keywords

dementia cerebrovascular adverse events death antipsychotics

References

Devanand DP , Jacobs DM , Tang MX , et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997 ;54(3):257-263.

Jeste DV , Finkel SI Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry . 2000;8(1):29-34.

Paulsen JS , Salmon DP , Thal LJ , et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000 ;54(10):1965-1971.

Bharucha AJ , Rosen J. , Mulsant BH , Pollock BG Assessment of behavioral and psychological symptoms of dementia. CNS Spectr. 2002;7(11):797-802.

Lawlor B. Managing behavioural and psychological symptoms of dementia. Br J Psychiatry. 2002;181(6):463-465.

Alexopoulos GS , Streim J. , Carpenter D. , Docherty JP Using antipsychotic agents in older patients . J Clin Psychiatry. 2004;65(suppl 2):5-104.

Schneider LS , Pollock VE , Lyness SA A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990 ;38(5):553-563.

Schneider LS , Tariot PN , Dagerman KS , et al. Effectiveness and safety of atypical antipsychotic drugs in patients with Alzheimers disease . N Engl J Med. 2006;355(15):1525-1538.

Sultzer DL , Davis SM , Tariot PN , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-854.

10.

Rosenheck RA , Leslie DL , Sindelar JL , et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007;64(11):1259-1268.

11.

Siddique H. , Hynan LS , Weiner MF Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer’s dementia. J Clin Psychiatry. 2009;70(6):915-918.

12.

Ling Z. , Wendy JM , Dagerman KS , et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166(5):583-590.

13.

Gill SS , Bronskill SE , Normand ST , et al. Antipsychotic drug use and mortality in older adults with dementia . Ann Intern Med. 2007;146(11):775-786.

14.

Sink KM , Holden KF , Yaffe K. Pharmacologic treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.

15.

Ballard CG , Waite J. , Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease (Review). Cochrane Database Syst Rev. 2009;4:1-128.

16.

De Deyn PP , Rabheru K. , Rasmussen A. , et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia . Neurology. 1999;53(5):946-955.

17.

Herrmann N. , Lanctot KL

Do atypical antipsychotics cause stroke?

CNS Drugs. 2005;19(2):91-103.

18.

http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm . Accessed January 31, 2010.

19.

U.S. Food and drug administration. Public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. FDA talk paper T05-13. Rockville, MD : Food and Drug Administration; April 11, 2005. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm053171.htm . Accessed September 10, 2009.

20.

Brodaty H. , Ames D. , Snowdon J. , et al. A randomized placebo-controlled trial of Risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64(2):134-143.

21.

De Deyn PP , Katz IR , Brodaty H. , Lyons B. , Greenspan A. , Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg . 2005;107(6):497-508.

22.

Schneider LS , Dagerman K. , Insel PS Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.

23.

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdf. Accessed November 23, 2010.

24.

Sacchetti E. , Turrina C. , Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systemic review. Drug Saf. 2010;33(4):273-288.

25.

Herrmann N. , Mamdani M. , Lanctôt KL Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004; 161(6):1113-1115.

26.

Finkel S. , Kozma C. , Long S. , et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17(4): 617-629.

27.

Liperoti R. , Gambassi G. , Lapane KL , et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics . J Clin Psychiatry. 2005;66(9):1090-1096.

28.

Formiga F. , Fort I. , Pe′rez-Castejo′n JM, Ruiz D. , Duaso E. , Riu S. Association between risperidone treatment and cerebrovascular adverse events in elderly patient with dementia. J Am Geriatr Soc. 2005;53(8):1446-1448.

29.

Gill SS , Rochon PA , Herrmann N. , et al. Atypical antipsychotic drugs and risk of ischemic stroke: population based retrospective cohort study. BMJ. 2005 ;330(7489):445-448.

30.

Moretti R. , Torre P. , Antonello RM , Cattaruzza T. , Cazzato G. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J Neurol. 2005;252(10):1186-1193. doi:10.1007/ s00415-005-0830-z.

31.

Layton D. , Harris S. , Wilton LV , Shakir SA Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19(5):473-482.

32.

Percudani M. , Barbui C. , Fortino I. , Tansella M. , Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol . 2005;25(5): 468-470.

33.

Kolanowski A. , Fick D. , Waller JL , Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):217-225.

34.

Barnett MJ , Wehring H. , Perry PJ Comparison of risk of cerebrovasculer events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27(6):595-601.

35.

Wang PS , Schneeweiss S. , Setoguchi S. , et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27(6):707-710.

36.

Sacchetti E. , Trifiro G. , Caputi A. , et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects . J Psychopharmacol. 2008 ;22(1):39-46.

37.

Douglas IJ , Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.

38.

Chan MC , Chong CS , Wu AY , et al. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. Int J Geriatr Psychiatry. 2010;25(4): 362-370.

39.

Ballard C. , Hanney ML , Theodoulou M. , et al, DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long term follow-up of a randomized placebo-controlled trial . Lancet Neurol. 2009;8(2):151-157.

40.

Schneider LS , Dagerman KS , Insel PS Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA. 2005;294(15): 1934-1943.

41.

Nasrallah HA , White T. , Nasrallah AT Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol preliminary analysis of retrospective data. Am J Geriatr Psychaitry . 2004;12(4):437-439.

42.

Raivio MM , Laurila JV , Strandberg TE , Tilvis RS , Pitkala KH Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study . Am J Psychiatry. 2005;162(5):1027.

43.

Barnett MJ , Perry PJ , Alexander B. , Kaboli PJ Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol. 2006;26(2): 182-187.

44.

Suh GH , Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr . 2005;17(3):429-441.

45.

Nonino F. , Girolamo GD , Gamberini L. , Goldoni CA Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study. Neurol Sci. 2006;27(6): 375-380.

46.

Schneeweiss S. , Setoguchi S. , Brookhart A. , Dormuth C. , Wang PS Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632.

47.

Liperoti R. , Onder G. , Landi F. , et al. All-cause mortality associated with atypical and conventional antipsychotics among nursin home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340-1347.

48.

Rossom RC , Rector TS , Lederle FA , Dysken MW

Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?

J Am Geriatr Soc. 2010;58(6):1027-1034.

49.

Smith DA , Beier MT Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism . J Am Med Dir Assoc. 2004;5(2):129-132.